1-5 of 5
Ibrahim Haznedaroglu
Close
Sort by
Journal Articles

Meter: A Multi-Country, Real-World Chart Review Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients with Myelofibrosis

Vikas Gupta, Ciprian Tomuleasa, Gilberto Israel Barranco Lampon, Hsin-An Hou, Grzegorz Helbig, Argiris S. Symeonidis, Ibrahim Haznedaroglu, Kenny Galvez, Fernando Tatsch, Avijeet S Chopra, Meng Zhang, Tamas Vizkelety, David M Ross
Journal: Blood
Blood (2023) 142 (Supplement 1): 3205.
https://doi.org/10.1182/blood-2023-173942
Published: 2023
Journal Articles

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

Clinical Trials & Observations
Michele Baccarani, Gianantonio Rosti, Fausto Castagnetti, Ibrahim Haznedaroglu, Kimmo Porkka, Elisabetta Abruzzese, Giuliana Alimena, Hans Ehrencrona, Henrik Hjorth-Hansen, Veli Kairisto, Luciano Levato, Giovanni Martinelli, Arnon Nagler, Johan Lanng Nielsen, Ugur Ozbek, Francesca Palandri, Fausto Palmieri, Fabrizio Pane, Giovanna Rege-Cambrin, Domenico Russo, Giorgina Specchia, Nicoletta Testoni, Ole Weiss-Bjerrum, Giuseppe Saglio, Bengt Simonsson
Journal: Blood
Blood (2009) 113 (19): 4497–4504.
https://doi.org/10.1182/blood-2008-12-191254
Published: 2009
Includes: Supplemental data
Journal Articles

A Prospective Study of Imatinib 400 mg vs 800 mg Frontline in High Risk Ph+ Chronic Myeloid Leukemia (CML) Patients.

Michele Baccarani, MD, Fausto Castagnetti, MD, Kimmo Porkka, MD, Johan L. Nielsen, MD, Henrik Hjorth-Hansen, MD, Ibrahim Haznedaroglu, MD, Arnon Nagler, MD, Giovanna Rege-Cambrin, MD, Giorgina Specchia, MD, Marilina Amabile, BD, Nicoletta Testoni, BD, Francesca Palandri, MD, Fabrizio Pane, MD, Giuliana Alimena, MD, Giovanni Martinelli, MD, Gianantonio Rosti, MD, Bengt Simonsson, MD
Journal: Blood
Blood (2007) 110 (11): 26.
https://doi.org/10.1182/blood.V110.11.26.26
Published: 2007
Journal Articles

Imatinib High Dose (800 mg): Results of a Phase II Trial of the GIMEMA (Gruppo Italiano Malattie Ematologiche Dell’Adulto) CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.

Gianantonio Rosti, MD, Fausto Castagnetti, MD, Marilina Amabile, BD, Nicoletta Testoni, BD, Angela Poerio, BD, Giulia Marzocchi, BD, Massimo Breccia, MD, Francesca Palandri, MD, Tamara Intermesoli, MD, Fabio Stagno, MD, Giorgina Specchia, MD, Elisabetta Abruzzese, MD, Panagiota Giannoulia, MD, Giuseppe Saglio, MD, Fabrizio Pane, MD, Francesca Rancati, BD, Arnon Nagler, MD, Ibrahim Haznedaroglu, MD, Kimmo PorkKa, MD, Henrik Hjorth-Hansen, MD, Johan L. Nielsen, MD, Bengt Simonsson, MD, Giovanni Martinelli, MD, Michele Baccarani, MD
Journal: Blood
Blood (2006) 108 (11): 4776.
https://doi.org/10.1182/blood.V108.11.4776.4776
Published: 2006
Journal Articles

Imatinib 800 mg: Preliminary Results of a Phase II Trial of the GIMEMA CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.

Gianantonio Rosti, MD, Giovanni Martinelli, MD, Fausto Castagnetti, MD, Nicoletta Testoni, BD, Giorgina Specchia, MD, Renato Bassan, MD, Fabio Stagno, MD, Massimo Breccia, MD, Elisabetta Abruzzese, MD, Giuseppe Saglio, MD, Fabrizio Pane, MD, Bengt Simonsson, MD, Johan L. Nielsen, MD, Henrik Hjorth-Hansen, MD, Kimmo PorkKa, MD, Ibrahim Haznedaroglu, MD, Arnon Nagler, MD, Marco Vignetti, MD, Domenico Russo, MD, Marilina Amabile, BD, Michele Baccarani, MD
Journal: Blood
Blood (2005) 106 (11): 1098.
https://doi.org/10.1182/blood.V106.11.1098.1098
Published: 2005